Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. Wen, P. Y., Mellinghoff, I. K., Buxton, M., Cavenee, W. K., Colman, H., De Groot, J., Ellingson, B. M., Gordon, G. B., Khasraw, M., Lassman, A. B., Lim, M., Perry, J. R., Tanner, K., Weller, M., Yung, W., Cloughesy, T., GBM AGILE Investigators LIPPINCOTT WILLIAMS & WILKINS. 2021
View details for DOI 10.1200/JCO.2021.39.15_suppl.TPS2074
View details for Web of Science ID 000708120306194